BrainsWay's SWIFT Reimbursement Beat Is Real; the PTSD Silence Is Louder
A 70-million-life reimbursement surprise and a 78% gross margin make the quarter, but a slipped PTSD timeline and opaque minority investments keep the story from being clean.
BWAY.TA · Earnings Call · 2026-11-10
The reimbursement beat is the quarter
BrainsWay's Q3 was not just another 30%-plus revenue print. The number that matters is in the reimbursement paragraph: “more than 70 million covered lives in the U.S. now have access to reimbursement policies covering our SWIFT accelerated protocol” — Hadar Levy, Chief Executive Officer · 2026-11-10. Three months earlier, management was targeting a much smaller number: “I do expect to get reimbursement by payers for, I would say, 40 million to 50 million covered lives before the end of the year” — Hadar Levy, Chief Executive Officer · 2026-05-13. By August it was framing 57 million lives as eligible. Now the company says the figure is “much more than we expected to be at this time of the year,” and the demand mix is already shifting — “close to 50% from all new demands coming from the customer demand and request for the SWIFT protocol” — Hadar Levy, Chief Executive Officer · 2026-11-10.
The operating print followed: “we shipped 130 Deep TMS systems, representing 44% year-over-year growth” — Hadar Levy, Chief Executive Officer · 2026-11-10; global installed base crossed 2,000 systems; revenue rose 34% to $18.1 million; and remaining performance obligations reached roughly $85 million, up 31%. The expanding installed base matters because BrainsWay's model is increasingly lease-like and enterprise-led. Each system is a multiyear revenue stream, not a one-time device sale. That is why the RPO number is more important than the quarterly revenue beat. It also explains why management keeps returning to good visibility — a phrase that has become part of the BrainsWay vocabulary as the model shifts from device sales to recurring revenue.
This is not a market-wave story. The global keyword board is dominated by tariff refunds, Fed language and AI infrastructure; BrainsWay's reimbursement catalyst is company-specific. The closest global adjacency is the broad “Medical Solutions” and “Pharma Services” cluster, but those are not the same demand driver. BrainsWay is creating its own payer catalyst.
Operating leverage stops being a promise
The margin line is the second change. Gross margin reached 78%, up from 75% a year ago and in Q2. Operating income doubled to $2.6 million; operating margin went from 9% to 14%. Adjusted EBITDA rose 92% to $3.9 million, a 21% margin versus 15%. For a small-cap medtech that has spent years building commercial infrastructure, this is the first clean proof that revenue is dropping to profit.
Management also gave a more explicit cost frame for 2027: gross-margin gains from bill-of-materials and lower royalty payments are sustainable, and OpEx should grow only 15-20% next year while revenue growth continues. The CEO's summary was unusually direct:
with the hope that almost every dollar which is going to hit the top line revenue will go down to the EBITDA and even more into the net income.
That is the operating-leverage promise in one sentence. The qualifier is “hope,” but the Q3 numbers make it more than a slide. Book-to-bill remains around 1.3-1.4x, and the RPO backlog gives 2027 a visible starting point. If the company can hold gross margin near 78% and keep OpEx growth in the high teens, the incremental-margin math is powerful.
The silence around PTSD is louder than the SWIFT beat
The most important negative is what management did not say. In May, BrainsWay expected FDA clearance for comorbid PTSD before the end of the year: “we do expect to receive the FDA clearance before the end of the year” — Hadar Levy, Chief Executive Officer · 2026-05-13. On this call, PTSD appears in prepared remarks only as “we continue to work through the regulatory review process” — Hadar Levy, Chief Executive Officer · 2026-11-10, with no timeline and no explanation. The comorbid PTSD theme, which was a top-20 keyword last quarter, has dropped out of the current top-30. That is a conceptual fall-off, not just a ranking quirk. PTSD was supposed to be a near-term, low-incremental-cost indication on the existing installed base. A delay does not break the SWIFT story, but it removes a catalyst and raises a regulatory-timing question that management did not address.
The second soft spot is Neurolief. The home use opportunity is real — “we initiated a convertible loan in the amount of $11 million to Neurolief” — Hadar Levy, Chief Executive Officer · 2026-11-10 — but it is still not consolidated and still early. A quarter ago management said it would monitor the soft launch “what we would like to monitor is kind of in the next 90 days, what we call as a soft launch” — Hadar Levy, Chief Executive Officer · 2026-08-12. This quarter it said commercialization “remains at early stage” and gave no metrics. The home-use option is long-dated optionality, not a 2027 earnings driver.
The minority-investment program is the third opacity. Management has moved from six minority investments to “we've made close to 10 minority investment or following up investments or partnership” — Hadar Levy, Chief Executive Officer · 2026-11-10, with each portfolio company expected to open 50 or more locations over three years. But orders are “not linear,” the first year is slow, and management now says it will share more information in 2027. That is a reasonable venture-style strategy, but it is also a capital-allocation program that analysts cannot underwrite with numbers yet. The Radial Health investment ($3 million Series A) is the latest example; it may deepen commercial ties, but it does not change the near-term P&L.
The quieter durable driver is OCD. BrainsWay has crossed 1,000 OCD systems deployed, and reimbursement coverage is now about 180 million lives. The OCD coil is not a new theme, but it is a high-value installed-base expansion tool: the same system, a different coil, a severe patient population with few alternatives. The analyst noted 17% growth in OCD; the CEO confirmed it and pointed to the installed base. That is the kind of boring, repeatable demand that supports a recurring model.
What to underwrite
The quarter supports a higher-quality growth story: a genuine SWIFT reimbursement inflection, a larger OCD installed base, and visible operating leverage. The clinical evidence engine also keeps producing: the suicidal ideation analysis showed a 70% relative reduction over six weeks in a secondary analysis, and the peer reviewed publication is the kind of evidence that payers and psychiatrists actually read. Those are not revenue today, but they widen the moat.
The risks are timing and disclosure. PTSD has slipped without a new date; Neurolief is early; the minority-investment program is strategically interesting but financially opaque until 2027. The stock has no price tape in this context, so the report has to stand on operating evidence. On that evidence, BrainsWay is no longer just a TMS device seller — it is becoming a reimbursement-driven, recurring-revenue neurostimulation platform. The next proof point is 2027 guidance and any PTSD update. Until then, the 70-million-life SWIFT number is the one to anchor on.